What is the recommended pain management approach for a patient with opioid use disorder?

Pain Management in Patients with Opioid Use Disorder

Continue medications for opioid use disorder (MOUD) and add multimodal analgesia—never discontinue buprenorphine or methadone to treat pain, as this increases overdose risk and worsens outcomes. 1, 2, 3

Core Principle: Maintain MOUD Throughout Pain Treatment

The fundamental error clinicians make is stopping buprenorphine or methadone when patients develop acute or chronic pain. This approach is dangerous and counterproductive. Patients on MOUD have:

• Opioid tolerance requiring higher analgesic doses
• Risk of withdrawal if MOUD is stopped
• Potential opioid-induced hyperalgesia
• Increased overdose risk if suddenly exposed to full agonists without their maintenance therapy 1

For Patients on Buprenorphine

Acute Pain Management

Option 1 (Preferred): Continue buprenorphine at current dose and add short-acting full opioid agonists (morphine, hydromorphone, oxycodone), titrating to effect 1, 2, 1. Higher doses will be needed due to buprenorphine's high μ-receptor affinity—expect to use 2-3 times typical opioid doses. Monitor closely for respiratory depression with naloxone available.

Option 2: Divide daily buprenorphine into every 6-8 hour dosing to leverage its analgesic properties (e.g., 32mg daily becomes 8mg every 6 hours), plus add full agonist opioids as needed 1, 2, 1.

Option 3 (Inpatient only): Convert buprenorphine to methadone 30-40mg daily, which prevents withdrawal while allowing full agonist opioids to work predictably. Resume buprenorphine after pain resolves using proper induction protocol 1.

Chronic Pain Management

1. First step: Increase buprenorphine dose in divided dosing (4-16mg every 8 hours has shown benefit) 2
2. Second step: Consider switching from sublingual buprenorphine/naloxone to transdermal buprenorphine alone, which bypasses first-pass metabolism and may provide superior analgesia 2
3. Third step: Add high-potency full agonists (fentanyl, morphine, hydromorphone) at higher-than-usual doses 2
4. Final step: If inadequate response, transition from buprenorphine to methadone maintenance 2

For Patients on Methadone

Continue the daily methadone dose—it provides NO analgesia for acute pain despite preventing withdrawal 1. The methadone dose maintains baseline opioid requirements only.

Add separate opioid analgesics:

• Use short-acting full agonists (morphine, hydromorphone, oxycodone) in addition to maintenance methadone
• Expect to need higher and more frequent doses due to tolerance
• Avoid mixed agonist-antagonists (pentazocine, nalbuphine, butorphanol) which precipitate withdrawal 1
• Avoid combination products with acetaminophen at high doses—prescribe opioid and acetaminophen separately to prevent hepatotoxicity 1

If hospitalized and NPO:

Convert oral methadone to parenteral at 50-66% of oral dose, divided into 2-4 daily doses 1

Multimodal Analgesia Framework (Essential for All Patients)

Layer these interventions—opioids alone are insufficient:

1. Non-opioid analgesics: NSAIDs and acetaminophen unless contraindicated 4, 5, 6
2. Regional anesthesia: Nerve blocks, epidurals for surgical/procedural pain 5, 6
3. Adjuvant medications:
   • Ketamine (particularly effective in opioid-tolerant patients) 5, 6
   • Gabapentinoids for neuropathic pain
   • Antidepressants (SNRIs, TCAs)
   • Topical agents (lidocaine, capsaicin)
4. Non-pharmacologic: Physical therapy, cognitive-behavioral therapy, interventional procedures 4

Critical Safety Considerations

Avoid These Errors:

• Never abruptly discontinue MOUD—this dramatically increases overdose death risk 4, 3
• Never prescribe benzodiazepines concurrently with opioids or MOUD 4, 7, 3
• Never use mixed agonist-antagonists (pentazocine, nalbuphine) in patients on MOUD—they precipitate severe withdrawal 1

Monitor Closely:

• Respiratory rate and sedation level, especially when adding full agonists to buprenorphine 1
• Keep naloxone immediately available 1
• Review prescription drug monitoring program (PDMP) data 4, 7
• Coordinate with addiction treatment providers—notify methadone clinics of hospitalizations and medication changes 1

Chronic Pain in OUD: Long-Term Strategy

Prioritize non-opioid therapies—evidence shows opioids provide minimal benefit for chronic non-cancer pain with substantial harm 4, 3. For patients already on long-term opioids:

1. Assess for OUD using DSM-5 criteria 3
2. If OUD present, offer evidence-based treatment: buprenorphine or methadone maintenance (preferred over naltrexone) 4, 3
3. Implement slow, consensual taper if appropriate, with detailed documentation and taper agreement 8
4. Set realistic functional goals—complete pain elimination is unlikely 4
5. Establish treatment agreements specifying monitoring, urine drug testing, and conditions for continuation 4, 7

Special Populations

Pregnancy: Use buprenorphine (without naloxone) or methadone—both improve maternal outcomes and are superior to no treatment 3

Perioperative: Continue MOUD throughout surgical period. Add multimodal analgesia and supplemental opioids as above 1, 2, 1

Emergency Department: Continue MOUD, add short-acting opioids and non-opioid adjuncts. Single studies suggest clonidine or haloperidol/midazolam combinations may help but require validation 6

Documentation and Communication

Document thoroughly:

• Pain diagnosis and functional goals
• Rationale for opioid therapy
• PDMP review
• Substance use disorder assessment
• Treatment plan including taper schedule if applicable 8, 7

Coordinate care between pain management, addiction medicine, primary care, and mental health providers 8, 9. This is not optional—fragmented care leads to treatment failure and increased mortality.